Trials / Unknown
UnknownNCT04238975
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
Randomized, Double-blind, Active-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of GC3111 in Healthy Adults
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 213 (estimated)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 19 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety and efficacy (immunogenicity) of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19-64 years of age.
Detailed description
To evaluate immunogenicity of GC3111 as tetanus, diphtheria and acellular pertussis (Tdap) vaccine in healthy adults. To evaluate safety of GC3111 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC3111 vaccine | 0.5mL, Intramuscular |
| BIOLOGICAL | Boostrix® vaccine | 0.5mL, Intramuscular |
Timeline
- Start date
- 2019-10-14
- Primary completion
- 2021-02-01
- Completion
- 2021-05-01
- First posted
- 2020-01-23
- Last updated
- 2020-01-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04238975. Inclusion in this directory is not an endorsement.